Small-cell lung cancer (SCLC) is one of the most lethal cancers, with patients diagnosed with extensive-stage small-cell lung cancer (ES-SCLC) experiencing a median survival of just 12 months after ...

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

The FDA has accepted the application for lurbinectedin in combination with atezolizumab as first-line maintenance for ES-SCLC.

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Stephen V. Liu, MD, discusses the phase 3 IMforte study of lurbinectedin and atezolizumab in extended-stage small cell lung cancer.

Lurbinectedin and atezolizumab performed better than atezolizumab alone as maintenance therapy for extensive-stage small cell lung cancer.

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

Jazz Pharmaceuticals (JAZZ) stock gains as its lung cancer therapy Zepzelca, in combination with Roche's Tecentriq, receives ...

The timing of immunotherapy initiation is not a significant factor in the outcomes of patients with extensive-stage small ...

FDA granted priority review to Zepzelca plus Tecentriq for first-line maintenance in extensive-stage small cell lung cancer.

Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health ...